SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon.The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improvethe stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships.Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.

Pharmaceutical

Health Care

Biotechnology

SiSaf Ltd

Dr Suzanne Saffie-Siebert

Tim Brundle

Richard Scarrott

Nissim Torabi-Pour

John Stanton

Joanne Manson

Flavia M. Sutera

Charles Weatherstone

Andy Gibson

The Research and Development team at SiSaf Ltd focuses on advancing the application of its proprietary Bio-Courier® technology to enhance RNA delivery systems, particularly through the formulation of silicon-stabilized hybrid lipid nanoparticles (sshLNP). Comprising experts in formulation science and molecular biology, the team conducts extensive research to develop innovative RNA therapeutics aimed at treating rare genetic disorders, ensuring improvements in stability, safety, and transfection efficiency while collaborating with research partners to maximize the potential of their cutting-edge technology.

Research and Development

Leadership Team

Operations Team

Research and Development

About

Team members

Other teams at SiSaf Ltd

Leadership Team

Operations Team